Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1Dermatologic 1

Conditions

Carcinoma, Hepatocellular 13Liver Neoplasms 6Neoplasm Metastasis 3Recurrence 1Neoplastic Cells, Circulating 1Melanoma 1Colorectal Neoplasms 1

Interventions

pembrolizumab 59Nivolumab 34Cyclophosphamide 21fludarabine 15Paclitaxel 12Ipilimumab 12atezolizumab 11Specimen Handling 11Magnetic Resonance Spectroscopy 10Carboplatin 10Docetaxel 9Cisplatin 9Gemcitabine 8Biopsy 8durvalumab 7aldesleukin 7Radiosurgery 7Interleukin-2 7Bevacizumab 7cemiplimab 6Pemetrexed 6fludarabine phosphate 5avelumab 5Radiotherapy 5Drug Therapy 5spartalizumab 4epacadostat 4enzalutamide 4Taxes 4Sirolimus 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Melanoma × Chemoembolization, Therapeutic × Gastrointestinal × Clear all
NCT01336985 2019-12-17

Safety and Pharmacokinetics of Treating Liver Cancer With Drug-Eluting Beads

National Institutes of Health Clinical Center (CC)

Phase 1 Terminated
5 enrolled
DermatologicGastrointestinal

Liver Neoplasms, Melanoma, Neoplasm Metastasis, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡